Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeutic and commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.
Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed at combating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles.
Nomic develops a proteomic technology platform designed to understand, detect, and treat diseases with DNA nanotechnology. NPlex's platform and research provides cost-effective measurement of protein data with sample, fits seamlessly within industry cytometers for high-throughput analysis, and development of custom protein panels. It allows nanotechnology developers and businesses to bring improvement in existing instrument, workflow, and bring automation in the system.
Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. The company was founded in 2018 and is based in Israel, the Netherlands, and Boston.
Thryv Therapeutics Inc., previously called LQT Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. They have been pioneering a precision medicine approach to treat Long QT Syndrome via SGK1 inhibition since 2019 and have since evolved their portfolio to include the treatment of resistant and rare cancers. The development of SGK1 inhibitors represents a novel approach to target treatment-resistant cancers, and complement existing therapies. This strategic evolution has secured an additional US$15M financing fuelling Thryv to complete a proof-of-concept study for LQTS, and submit an IND for the treatment of resistant cancer. Thérapeutiques Thryv Inc, précédemment appelée Thérapeutiques QTL Inc, est une entreprise privée basée à Montréal, Québec, Canada. Depuis 2019, ils sont les pionniers d'une approche de médecine de précision pour traiter le syndrome du QT long via l'inhibition de SGK-1 et ont depuis évoluer pour inclure le traitement des cancers résistants et rares. Le développement des inhibiteurs de SGK-1 représente une nouvelle approche pour cibler les cancers résistants aux traitements, et compléter les thérapies existantes. Cette évolution stratégique a permis d'obtenir un financement supplémentaire de 15 millions de dollars US qui alimentera Thryv pour compléter une étude de preuve de concept pour le LQTS, et soumettre une IND pour le traitement des cancers résistantes.
Xap Therapeutics is a start-up biotechnology company that is developing an innovative, synthetic biology-driven platform for cell therapeutics. Xap Therapeutics, formed by biotech entrepreneurs, is a producer of a ''chassis'' cell which functions in cell therapies through genetically engineered constructs. Xap Therapeutics was established in 2017 by James Patterson, M.D., Ph.D in Cambridge, England.